La référence en hépatite C au Québec depuis 2003

Health Canada approves DAKLINZA

Published by CAPAHC on


BMS-daklinza-daclatasvir-hepatitis-CThis all-oral therapy without interferon and ribavirin was approved today by Health Canada.

Daklinza (daclatasvir) from BMS, is a INS5A inhibitor, for patients with genotype 1,2,3, with or without cirrhosis, in combination with sofosbuvir (Sovaldi), indicated for 12 or 24 weeks regimen.

Perhaps in Quebec next year.